Published in Blood on June 21, 2005
Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med (2011) 6.02
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood (2006) 4.46
In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood (2008) 2.23
High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood (2006) 2.21
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med (2013) 2.03
Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest (2010) 2.00
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res (2007) 2.00
Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood (2007) 1.96
Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood (2014) 1.95
Current issues in chronic graft-versus-host disease. Blood (2014) 1.83
Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood (2009) 1.80
Emergence of T cells that recognize nonpolymorphic antigens during graft-versus- host disease. Blood (2012) 1.48
Optimization of adipose tissue-derived mesenchymal stem cells by rapamycin in a murine model of acute graft-versus-host disease. Stem Cell Res Ther (2015) 1.40
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica (2012) 1.39
Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol (2010) 1.35
Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood (2011) 1.16
B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood (2012) 1.15
Oral graft-versus-host disease. Oral Dis (2008) 1.14
Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Invest (2015) 1.13
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. Biol Blood Marrow Transplant (2015) 1.12
CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity. J Immunol (2012) 1.12
The IL-17 differentiation pathway and its role in transplant outcome. Biol Blood Marrow Transplant (2012) 1.11
ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci Transl Med (2015) 1.10
Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine. Exp Hematol (2007) 1.07
Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Immunotherapy (2009) 1.07
Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res (2007) 1.06
Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease. Clin Cancer Res (2011) 1.06
Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2009) 1.05
Biology of chronic graft-versus-host disease: implications for a future therapeutic approach. Keio J Med (2008) 0.99
Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood (2015) 0.98
Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood (2016) 0.96
The role of regulatory T cells in the biology of graft versus host disease. Front Immunol (2013) 0.96
Current and future approaches for control of graft-versus-host disease. Expert Rev Hematol (2008) 0.95
Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood (2016) 0.94
Rabbit antithymocyte globulin (thymoglobulin) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients. Haematologica (2012) 0.94
Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion. Ther Adv Hematol (2013) 0.93
Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. Haematologica (2009) 0.93
Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab. Haematologica (2009) 0.92
Extracorporeal Photochemotherapy as a Challenging Treatment for Cutaneous T-Cell Lymphoma, Acute and Chronic Graft-versus-Host Disease, Organ Rejection and T-Lymphocyte-Mediated Autoimmune Diseases. Transfus Med Hemother (2007) 0.91
Predicting the Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: The Long and Winding Road toward Validated Immune Biomarkers. Front Immunol (2013) 0.90
Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica (2012) 0.89
Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood (2011) 0.88
Increased Th17/Treg ratio in chronic liver GVHD. Bone Marrow Transplant (2014) 0.87
c-Rel is an essential transcription factor for the development of acute graft-versus-host disease in mice. Eur J Immunol (2013) 0.87
The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. Korean J Hematol (2011) 0.86
A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2014) 0.86
Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease. J Leukoc Biol (2012) 0.86
Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD. Blood (2016) 0.86
Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF. J Immunol (2013) 0.86
Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood (2016) 0.84
Reconstitution of self-tolerance after hematopoietic stem cell transplantation. Immunol Res (2010) 0.84
Immune reconstitution and graft-versus-host reactions in rat models of allogeneic hematopoietic cell transplantation. Front Immunol (2012) 0.83
Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation. Sci Transl Med (2009) 0.83
Kinetics of lymphocyte reconstitution after allogeneic bone marrow transplantation: markers of graft-versus-host disease. J Leukoc Biol (2011) 0.83
Interleukin-10 spot-forming cells as a novel biomarker of chronic graft-versus-host disease. Haematologica (2012) 0.83
Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. Stem Cell Investig (2016) 0.82
Tregs, HSCT, and acute GVHD: up close and personal. Blood (2013) 0.81
Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031. Biol Blood Marrow Transplant (2011) 0.81
Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant (2015) 0.81
Blockade of interleukin 27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing FOXP3 expression. Blood (2016) 0.81
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica (2014) 0.80
Innate immune activation by the viral PAMP poly I:C potentiates pulmonary graft-versus-host disease after allogeneic hematopoietic cell transplant. Transpl Immunol (2010) 0.79
CD4+CD25highCD127low regulatory T cells in peripheral blood are not an independent factor for chronic graft-versus-host disease after allogeneic stem cell transplantation. ScientificWorldJournal (2012) 0.79
Evolution of the donor T-cell repertoire in recipients in the second decade after allogeneic stem cell transplantation. Blood (2011) 0.79
Curcumin attenuates acute graft-versus-host disease severity via in vivo regulations on Th1, Th17 and regulatory T cells. PLoS One (2013) 0.78
Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside. ScientificWorldJournal (2011) 0.78
Role of CD4CD25FOXP3 Regulatory T Cells in Psoriasis. Ann Dermatol (2010) 0.78
Chronic graft-versus-host disease: biological insights from pre-clinical and clinical studies. Blood (2016) 0.78
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood (2017) 0.78
Increased Foxp3(+)Helios(+) Regulatory T Cells and Decreased Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant (2017) 0.77
Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse? Haematologica (2009) 0.77
CD4+ T cells in aged or thymectomized recipients of allogeneic stem cell transplantations. Biol Res (2015) 0.77
CD25 preselective anti-HIV vectors for improved HIV gene therapy. Hum Gene Ther Methods (2013) 0.77
Biomarkers in chronic graft-versus-host disease. Expert Rev Hematol (2011) 0.77
Regulatory T-cell immunotherapy for allogeneic hematopoietic stem-cell transplantation. Ther Adv Hematol (2012) 0.77
Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study. Oncoimmunology (2016) 0.76
Y27, a novel derivative of 4-hydroxyquinoline-3-formamide, prevents the development of murine systemic lupus erythematosus-like diseases in MRL/lpr autoimmune mice and BDF1 hybrid mice. Arthritis Res Ther (2012) 0.76
High proportions of regulatory T cells in PBSC grafts predict improved survival after allogeneic haematopoietic SCT. Bone Marrow Transplant (2015) 0.76
The Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical Overview. Front Immunol (2016) 0.76
Novel regulatory therapies for prevention of Graft-versus-host disease. BMC Med (2012) 0.76
Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease. JCI Insight (2016) 0.75
Pre-transplant donor CD4(-) invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease. Leukemia (2016) 0.75
Minimal change disease in graft versus host disease: a podocyte response to the graft? Clin Nephrol (2013) 0.75
Previously Activated Psoralen: A Possible Novel Format of Psoralen Used in the Treatment of Graft-versus-host Disease. West Indian Med J (2015) 0.75
c-Rel in GVHD biology: a missing link. Eur J Immunol (2013) 0.75
Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation. Int J Hematol Oncol (2015) 0.75
Anti-CMV-IgG positivity of donors is beneficial for alloHSCT recipients with respect to the better short-term immunological recovery and high level of CD4+CD25high lymphocytes. Viruses (2015) 0.75
Aqueous extract of Caesalpinia sappan decelerates allograft rejection by inducing imbalance between CD4(+) CD25(+) T cells and Th17 cells. Int J Clin Exp Med (2015) 0.75
B-Cell-Based and Soluble Biomarkers in Body Liquids for Predicting Acute/Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol (2017) 0.75
A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica (2016) 0.75
Role of thymic stromal lymphopoietin (TSLP) in palifermin-mediated immune modulation and protection from acute murine graft-versus-host disease. J Clin Immunol (2010) 0.75
Humanized Chronic Graft-versus-Host Disease in NOD-SCID il2rγ-/- (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation. PLoS One (2015) 0.75
Mechanistic approaches for prevention and treatment of chronic GVHD. Blood (2016) 0.75
Genetic Association of Hematopoietic Stem Cell Transplantation Outcome beyond Histocompatibility Genes. Front Immunol (2017) 0.75
Notch Signaling and Alloreactivity. Transplantation (2016) 0.75
Advances in the Use of Regulatory T-Cells for the Prevention and Therapy of Graft-vs.-Host Disease. Biomedicines (2017) 0.75
Tbet is a critical modulator of FoxP3 expression in autoimmune graft versus host disease. Haematologica (2017) 0.75
Therapeutic immune monitoring of CD4(+)CD25(+) T cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Oncol Lett (2017) 0.75
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity (2005) 23.00
An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol (2003) 19.16
CD4+CD25high regulatory cells in human peripheral blood. J Immunol (2001) 11.25
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med (2004) 8.98
CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med (2003) 7.78
Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med (2001) 7.46
Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med (2002) 6.11
CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med (2003) 6.00
The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood (2002) 5.72
Chronic graft-versus-host disease. Biol Blood Marrow Transplant (2003) 5.36
A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods (2002) 4.48
Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol (2001) 3.99
CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med (2002) 3.70
Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol (2004) 2.88
Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest (2003) 2.85
CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol (2004) 2.45
Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2002) 2.40
Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood (2004) 2.20
Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant (2001) 1.82
Development and function of CD25+CD4+ regulatory T cells. Curr Opin Immunol (2004) 1.63
Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant (2003) 1.62
Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet (2002) 1.49
CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood (2003) 1.41
Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation. Eur J Immunol (2003) 1.35
Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood (2003) 1.33
T-cell receptor excision circle and T-cell dynamics after allogeneic stem cell transplantation are related to clinical events. Blood (2002) 1.31
Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation. Transplantation (2002) 1.27
Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood (2001) 1.24
Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant (2002) 1.23
Chronic graft-vs-host disease. JAMA (2003) 1.16
Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol (2004) 1.01
Chronic intestinal graft-versus-host disease: clinical, histological and immunohistochemical analysis of 17 children. Bone Marrow Transplant (2002) 0.95
Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation. Blood (1993) 0.90
Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant (2001) 0.87
Increased numbers of CD8+CD11+, CD8+CD11- and CD8+Leu7+ cells in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant (1990) 0.86
Marked increase of CD8+S6F1+ and CD8+CD57+ cells in patients with graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant (1994) 0.83
Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood (2003) 20.10
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med (2012) 6.30
Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med (2011) 6.02
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol (2002) 4.69
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood (2006) 4.46
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med (2011) 3.83
Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant (2007) 3.58
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood (2002) 3.56
Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med (2013) 3.39
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med (2013) 3.27
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med (2014) 3.24
Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med (2005) 3.19
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood (2006) 3.08
Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood (2011) 3.02
Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. Arch Dermatol (2006) 2.92
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood (2004) 2.89
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol (2011) 2.78
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood (2011) 2.66
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood (2007) 2.54
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood (2006) 2.53
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood (2009) 2.50
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol (2008) 2.44
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant (2006) 2.44
Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood (2009) 2.44
A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast. Plast Reconstr Surg (2011) 2.43
Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood (2011) 2.41
Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2002) 2.40
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res (2010) 2.34
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood (2011) 2.33
The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol (2011) 2.31
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood (2004) 2.30
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood (2011) 2.26
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant (2006) 2.24
Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood (2012) 2.19
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis (2013) 2.17
Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood (2010) 2.17
Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood (2013) 2.12
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 2.11